Literature DB >> 3782489

Immune haemolytic anaemia and nomifensine treatment in north west England 1984-85: report of six cases.

V J Martlew.   

Abstract

Nomifensine, an antidepressant used for eight years in Britain, was particularly popular in the north west of England. Haemolytic anaemia was recognised as a rare side effect, but in 1984 a cluster of six cases was referred to the North West Regional Transfusion Centre, reflecting an incidence of 0.006%. These were collected within 18 months and showed variable serological features, indicating that antibodies associated with nomifensine treatment are neither rare nor of one particular type. The accumulation of this and similar data contributed to its withdrawal from the British market in January, 1986.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782489      PMCID: PMC500240          DOI: 10.1136/jcp.39.10.1147

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Fatal immune haemolysis associated with nomifensine.

Authors:  R J Sokol; S Hewitt; D J Booker; R Stamps; M Taylor; R M Stewart
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

2.  Massive intravascular haemolysis during treatment of nomifensine.

Authors:  K Lylloff; C Jersild; T Bacher; O Slot
Journal:  Lancet       Date:  1982-07-03       Impact factor: 79.321

3.  Acute haemolysis and renal failure after nomifensine overdosage.

Authors:  L F Prescott; R N Illingworth; J A Critchley; I Frazer; M L Stirling
Journal:  Br Med J       Date:  1980-11-22

4.  The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia.

Authors:  A Salama; C Mueller-Eckhardt
Journal:  N Engl J Med       Date:  1985-08-22       Impact factor: 91.245

5.  Anti-nomifensine antibody causing immune hemolytic anemia and renal failure.

Authors:  B Habibi; J P Cartron; M Bretagne; P Rouger; C Salmon
Journal:  Vox Sang       Date:  1981-02       Impact factor: 2.144

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.